MedTrace Logo

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00953524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 849

Last updated 2014-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine.

Primary Objectives:

* To describe the immunogenicity of the candidate vaccines after each injection.
* To describe the safety of the candidate vaccines after each injection.

Conditions

Interventions

BIOLOGICAL

Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)

0.5 mL, Intramuscular on Day 0 and on Day 21

BIOLOGICAL

Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)

0.5 mL, Intramuscular on Day 0 and Day 21

BIOLOGICAL

Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)

0.5 mL, Intramuscular on Day 0 and day 21

BIOLOGICAL

Normal saline solution (placebo)

0.5 mL, Intramuscular on Day 0 and Day 21

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Sanofi Pasteur Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-03-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953524 on ClinicalTrials.gov